10% Off
Rozy0.5 mg+0.2
Square Pharmaceuticals PLC.
৳12.60
Add to cart
Generic medicine
Ethinylestradiol + Drospirenone [For hormone replacement therapy]: Brands, Price & Uses in Bangladesh
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is indicated for use in postmenopausal women as combined estrogen-progestin hormone replacement therapy (HRT).
About Ethinylestradiol + Drospirenone [For hormone replacement therapy]
Indications of Ethinylestradiol + Drospirenone [For hormone replacement therapy]
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is indicated for use in postmenopausal women as combined estrogen-progestin hormone replacement therapy (HRT). Evidence-based indications include:
- Established/approved use: Treatment of moderate to severe vasomotor symptoms (hot flashes, night sweats) associated with menopause.
- Established/approved use: Treatment of moderate to severe symptoms of vulvovaginal atrophy due to menopause (when systemic therapy is appropriate).
- Guideline-supported use: Endometrial protection in women with an intact uterus who are receiving estrogen therapy — the progestin component (drospirenone) opposes estrogen-induced endometrial proliferation, reducing the risk of endometrial hyperplasia/cancer.
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is not indicated for contraception, and this hormone replacement therapy formulation should not be interchanged with contraceptive-labeled ethinylestradiol/drospirenone products, which are formulated and dosed for a different purpose.
Dosage & Administration of Ethinylestradiol + Drospirenone [For hormone replacement therapy]
General Dosing Principles
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is taken as one tablet daily, continuously, without a hormone-free interval, at approximately the same time each day, with or without food.
| Indication | Typical Adult Dosage |
|---|---|
| Vasomotor symptoms of menopause | One tablet once daily, continuous combined regimen |
| Vulvovaginal atrophy (systemic therapy) | One tablet once daily, continuous combined regimen |
| Endometrial protection (with intact uterus) | Included automatically as part of the fixed-dose combination taken once daily |
Treatment with Ethinylestradiol + Drospirenone [For hormone replacement therapy] should use the lowest effective dose for the shortest duration consistent with treatment goals; the need for continued therapy should be reassessed periodically by the prescribing physician (see Duration of Treatment).
Side Effects of Ethinylestradiol + Drospirenone [For hormone replacement therapy]
Common side effects of Ethinylestradiol + Drospirenone [For hormone replacement therapy] include headache, breast tenderness/pain, nausea, bloating, irregular or breakthrough vaginal bleeding/spotting (especially in early cycles), and mood changes.
Less common but serious effects include venous thromboembolism, stroke, myocardial infarction, gallbladder disease, and hyperkalemia (particularly in at-risk patients — see Contraindications and Interactions). Patients should seek prompt medical attention for chest pain, sudden shortness of breath, leg swelling/pain, sudden severe headache, or vision changes while taking Ethinylestradiol + Drospirenone [For hormone replacement therapy].
Contraindications of Ethinylestradiol + Drospirenone [For hormone replacement therapy]
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is contraindicated in patients with:
- Known hypersensitivity to ethinylestradiol, drospirenone, or any excipient.
- Known, suspected, or past history of breast cancer or other known or suspected estrogen-dependent neoplasia.
- Undiagnosed abnormal genital/vaginal bleeding.
- Active or past history of venous thromboembolism (deep vein thrombosis, pulmonary embolism) or arterial thromboembolic disease (stroke, myocardial infarction), or known thrombophilic disorders.
- Known or suspected pregnancy.
- Severe hepatic impairment, active liver disease, or liver tumors (current or history), while liver function tests remain abnormal.
- Renal insufficiency (due to the hyperkalemia risk associated with drospirenone's anti-mineralocorticoid activity).
- Adrenal insufficiency.
Frequently Asked Questions about Ethinylestradiol + Drospirenone [For hormone replacement therapy]
What is Ethinylestradiol + Drospirenone [For hormone replacement therapy] used for?
Ethinylestradiol + Drospirenone [For hormone replacement therapy] is used in postmenopausal women to relieve moderate to severe hot flashes and night sweats, treat vulvovaginal atrophy due to menopause, and protect the uterine lining (endometrium) when estrogen therapy is given to a woman with an intact uterus.
Is Ethinylestradiol + Drospirenone [For hormone replacement therapy] the same as a birth control pill?
No. Although Ethinylestradiol + Drospirenone [For hormone replacement therapy] contains the same types of hormones used in some contraceptives, this specific formulation is labeled and dosed for hormone replacement therapy in menopause, not for contraception, and should not be substituted for a contraceptive product or vice versa.
Can Ethinylestradiol + Drospirenone [For hormone replacement therapy] cause high potassium levels?
Yes, it can. Drospirenone in Ethinylestradiol + Drospirenone [For hormone replacement therapy] has anti-mineralocorticoid (potassium-sparing) activity, so the risk of hyperkalemia is increased in people with kidney, liver, or adrenal problems, or those taking ACE inhibitors, ARBs, potassium-sparing diuretics, potassium supplements, or NSAIDs. A doctor may check blood potassium levels during the first treatment cycle in at-risk patients.
Who should not take Ethinylestradiol + Drospirenone [For hormone replacement therapy]?
Ethinylestradiol + Drospirenone [For hormone replacement therapy] should not be used by women who are pregnant or suspect they may be pregnant, have unexplained vaginal bleeding, have or have had breast cancer or another estrogen-dependent cancer, have a current or past history of blood clots (DVT, pulmonary embolism), stroke, or heart attack, have severe liver disease, or have kidney or adrenal insufficiency.
What are the serious risks of Ethinylestradiol + Drospirenone [For hormone replacement therapy]?
Combined hormone therapy such as Ethinylestradiol + Drospirenone [For hormone replacement therapy] carries an increased risk of blood clots, stroke, heart attack, gallbladder disease, and a small increase in breast cancer risk with long-term use; in women 65 and older it has also been linked to a higher risk of dementia. Seek urgent medical care for chest pain, sudden shortness of breath, leg swelling, sudden severe headache, or vision changes.
Can I take Ethinylestradiol + Drospirenone [For hormone replacement therapy] while breastfeeding?
Use of Ethinylestradiol + Drospirenone [For hormone replacement therapy] during breastfeeding is generally not recommended because estrogen can reduce milk supply and small amounts may pass into breast milk. Consult a physician, who will weigh the benefits against the potential risk to the infant before prescribing it.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.